18. Nucleic Acid Vaccination

  1. W. John W. Morrow PhD, DSc, FRCPath3,
  2. Nadeem A. Sheikh PhD4,
  3. Clint S. Schmidt PhD5 and
  4. D. Huw Davies PhD6
  1. Britta Wahren MD, PhD1 and
  2. Margaret A. Liu MD2

Published Online: 20 JUN 2012

DOI: 10.1002/9781118345313.ch18

Vaccinology: Principles and Practice

Vaccinology: Principles and Practice

How to Cite

Wahren, B. and Liu, M. A. (2012) Nucleic Acid Vaccination, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch18

Editor Information

  1. 3

    Seattle, WA, USA

  2. 4

    Dendreon Corporation, Seattle, WA, USA

  3. 5

    NovaDigm Therapeutics, Inc., Grand Forks, ND, USA

  4. 6

    University of California at Irvine, Irvine, CA, USA

Author Information

  1. 1

    Department of Virology, Karolinska Institutet and Swedish Institute for Infectious Disease Control, Stockholm, Sweden

  2. 2

    ProTherImmune, Lafayette, CA, USA

Publication History

  1. Published Online: 20 JUN 2012
  2. Published Print: 3 AUG 2012

ISBN Information

Print ISBN: 9781405185745

Online ISBN: 9781118345313



  • nucleic acids;
  • DNA vaccines;
  • immunotherapeutics;
  • infectious diseases


DNA vaccines can generate the type of immunity needed for protection against a variety of diseases, either via the induction of cross-strain cellular immune responses, or high levels of cellular immunity, and often humoral immunity. Modifications of DNA sequences are easily made and confer new properties, such as exposing desirable neutralizing antigens or adding cytokine-inducing properties. But the most compelling rationale for DNA vaccines is to offer the potential for making vaccines and therapeutics directed against diseases that to date have not been effectively addressed by earlier technologies, including chronic infections, cancers, and diseases due to genetic aberrations. The DNA technology may thus serve not only to deliver new vaccines but also as new immunotherapeutics in chronic diseases where additional long-term delivery of an endogenous substance is required.